ClassID:

20998

A61K38/25 - CPC Classification

Classification description:

Medicinal preparations containing peptides; Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans; Hormones Growth hormone-releasing factor [GH-RF] (Somatoliberin)

Recent Application in this class:
#1
20260115244
2026-04-30

INJECTABLE NUTRIENT SOLUTION

#2
20260097048
2026-04-09

TREATMENT OF PROSTATE CANCER WITH A COMBINATION OF ABIRATERONE ACETATE AND NIRAPARIB

#3
20260077018
2026-03-19

TREATMENT OF MILD TRAUMATIC BRAIN INJURY

#4
20250332223
2025-10-30

GHRH ANTAGONISTS FOR USE IN A METHOD OF TREATING SARCOIDOSIS

#5
20250241996
2025-07-31

COMBINATORIAL, AND ROTATIONAL COMBINATORIAL THERAPIES

#6
20250073277
2025-03-06

METHODS FOR OBTAINING CARDIOMYOGENIC PRECURSOR CELLS

#7
20240424001
2024-12-26

LOCAL DELIVERY OF GROWTH AND REPAIR PROMOTING COMPOUNDS FOR TREATING, REDUCING AND/OR PREVENTING STRESS URINARY INCONTINENCE AND FECAL INCONTINENCE

#8
20240307498
2024-09-19

GROWTH HORMONE-RELEASING HORMONE PEPTIDES AND FORMULATIONS THEREOF

#9
20240287153
2024-08-29

Treating Inflammatory Lung Disease

#10
20240181015
2024-06-06

EFFECT OF GHRH ANTAGONISTS IN DIABETES AND OBESITY

#11
20240091316
2024-03-21

GHRH or analogues thereof for use in treatment of hepatic disease

#12
20230414722
2023-12-28

Injectable presentations, syringes and compositions with sustained and/or controlled release of lanreotide

#13
20230393148
2023-12-07

KITS, REAGENTS AND METHODS FOR THE ASSESSMENT OF LIVER DISEASES

#14
20230390206
2023-12-07

METHOD OF DRUG FORMULATION BASED ON INCREASING THE AFFINITY OF ACTIVE AGENTS FOR CRYSTALLINE MICROPARTICLE SURFACES

#15
20230310471
2023-10-05

METHODS, DEVICES, AND SYSTEMS FOR TREATING LENS PROTEIN AGGREGATION DISEASES

#16
20230270865
2023-08-31

LOW-DOSE PHARMACEUTICAL COMPOSITIONS OF GHRH ANALOGS AND USES THEREOF

#17
20230218640
2023-07-13

TREATMENT OF PROSTATE CANCER WITH A COMBINATION OF ABIRATERONE ACETATE AND NIRAPARIB

#18
20230126533
2023-04-27

Method of treating an inflammatory disorder

#19
20220378880
2022-12-01

PHARMACEUTICAL COMPOSITIONS OF GHRH ANALOGS AND USES THEREOF

#20
20220288111
2022-09-15

Pharmaceutical compositions for delivery of peptide

#21
20220143149
2022-05-12

GHRH ANTAGONISTS FOR USE IN A METHOD OF TREATING SARCOIDOSIS

#22
20220000983
2022-01-06

Treating inflammatory lung disease

#23
20210353544
2021-11-18

METHOD OF DRUG FORMULATION BASED ON INCREASING THE AFFINITY OF ACTIVE AGENTS FOR CRYSTALLINE MICROPARTICLE SURFACES

#24
20210322519
2021-10-21

PHARMACEUTICAL COMPOSITIONS OF GHRH ANALOGS AND USES THEREOF

#25
20210252109
2021-08-19

Use of GHRP-6 as late cardioprotective and cardiac restoration medicament

#26
20210177943
2021-06-17

GHRH or analogues thereof for use in treatment of hepatic disease

#27
20210138024
2021-05-13

Manufacture of degarelix

#28
20210077564
2021-03-18

Manufacture of Degarelix

#29
20210023178
2021-01-28

Injectable presentations, syringes and compositions with sustained and/or controlled release of lanreotide

#30
20200405816
2020-12-31

GHRH or analogues thereof for use in treatment of hepatic disease

#31
20200360483
2020-11-19

METHOD FOR INHIBITING INFLAMMATION and PRO-INFLAMMATORY CYTOKINE/CHEMOKINE EXPRESSION USING A GHRELIN ANALOGUE

#32
20200353065
2020-11-12

Use of a growth hormone secretagogue peptide as a vaccine adjuvant

#33
20200347110
2020-11-05

Composition and Methods for Stimulating Gastrointestinal Motility

#34
20200306345
2020-10-01

GHRH or analogues thereof for use in treatment of hepatic disease

#35
20200297817
2020-09-24

PHARMACEUTICAL COMPOSITIONS OF GHRH ANALOGS AND USES THEREOF

#36
20200276273
2020-09-03

METHOD FOR TREATING MYELOID LEUKEMIA

#37
20200261541
2020-08-20

METHODS OF TREATING MILD BRAIN INJURY

#38
20200246389
2020-08-06

Methods for obtaining cardiomyogenic precursor cells

#39
20200188486
2020-06-18

Sucrose acetate isobutyrate-based compositions, methods and uses thereof

#40
20200121796
2020-04-23

Pharmaceutical compositions for delivery of peptide

#41
20190367945
2019-12-05

Method of treating type I diabetes using an AAV vector encoding uracortin 2

#42
20190290586
2019-09-26

Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents

#43
20190248861
2019-08-15

Composition and Methods for Stimulating Gastrointestinal Motility

#44
20190224271
2019-07-25

Manufacture of Degarelix

#45
20190209699
2019-07-11

Pegylated bioactive peptides and uses thereof

#46
20190029961
2019-01-31

Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces

#47
20180333466
2018-11-22

POSTPRANDIAL GASTROKINETIC AGENT

#48
20180289774
2018-10-11

Growth hormone releasing factor analogs and uses

#49
20180071367
2018-03-15

METHODS OF TREATING COGNITIVE IMPAIRMENTS OR DYSFUNCTION

#50
20180010148
2018-01-11

Method of treating type I diabetes using an AAV vector encoding uracortin 2

#51
20170342117
2017-11-30

Ghrelin splice variant for treating neuronal damage, neurodegenerative disease, parkinsons disease, alzheimers disease, and/or depression

#52
20170326166
2017-11-16

COMPOSITIONS AND METHODS FOR TREATING PITUITARY TUMORS

#53
20170319644
2017-11-09

Manufacture of Degarelix

#54
20170304403
2017-10-26

METHOD FOR INHIBITING INFLAMMATION and PRO-INFLAMMATORY CYTOKINE/CHEMOKINE EXPRESSION USING A GHRELIN ANALOGUE

#55
20170296628
2017-10-19

Pegylated bioactive peptides and uses thereof

#56
20170281732
2017-10-05

METHODS OF TREATING MILD BRAIN INJURY

#57
20170281549
2017-10-05

Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents

#58
20170274049
2017-09-28

Treatment of radiation injury using ghrelin

#59
20170266257
2017-09-21

METHODS OF TREATING TRAUMATIC BRAIN INJURY

#60
20170049858
2017-02-23

Stable formulations for parenteral injection of peptide drugs

#61
20170035855
2017-02-09

Method for suppressing malignant tumor metastasis

#62
20170035834
2017-02-09

Method of manufacture of GnRH-containing gel

#63
20160361267
2016-12-15

Nanoencapsulation of hydrophilic active compounds

#64
20160346212
2016-12-01

Method of drug formulation

#65
20160243197
2016-08-25

Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness

#66
20160166652
2016-06-16

NOVEL N- AND C-TERMINAL SUBSTITUTED ANTAGONISTIC ANALOGS OF GH-RH

#67
20160151287
2016-06-02

Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents

#68
20160051630
2016-02-25

Postprandial gastrokinetic agent

#69
20150359744
2015-12-17

Increasing drug affinity for crystalline microparticle surfaces

#70
20150258176
2015-09-17

Medicinal agent for suppressing malignant tumor metastasis

#71
20150218245
2015-08-06

Composition and methods for stimulating gastrointestinal motility

#72
20150174207
2015-06-25

METHODS FOR TREATING CANCER WITH GHRH AGONISTS

#73
20150148290
2015-05-28

Macrocyclic modulators of the ghrelin receptor

#74
20150141337
2015-05-21

Manufacture of degarelix

#75
20150011864
2015-01-08

Prevention of Mild Cognitive Impairment and Eventual Alzheimer's Disease

#76
20140378380
2014-12-25

USE OF UNACYLATED GHRELIN, FRAGMENTS AND ANALOGS THEREOF AS ANTIOXIDANT

#77
20140356319
2014-12-04

Compounds and pharmaceutical combinations for the treatment of neurodegenerative and ischemic brain diseases

#78
20140323402
2014-10-30

Protein Carrier-Linked Prodrugs

#79
20140314853
2014-10-23

Microspheres for controlled- or sustained-release delivery of therapeutics

#80
20140308358
2014-10-16

Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents

#81
20140206836
2014-07-24

N- and C-terminal substituted antagonistic analogs of GH-RH

#82
20140193378
2014-07-10

GHRH agonists for islet cell transplantation and function and the treatment of diabetes

#83
20140179604
2014-06-26

GHRH agonists for the treatment of ischemic disorders

#84
20140179600
2014-06-26

Stable formulations for parenteral injection of peptide drugs

#85
20140179599
2014-06-26

Stable formulations for parenteral injection of peptide drugs

#86
20140171362
2014-06-19

Stable formulations for parenteral injection of peptide drugs

#87
20140073570
2014-03-13

Pharmaceutical composition and methods for peptide treatment

#88
20140057847
2014-02-27

CARDIOPROTECTIVE EFFECTS OF GHRH AGONISTS

#89
20130345132
2013-12-26

Method of treatment of small for gestational age infants under two years of age

#90
20130261058
2013-10-03

ACCELERATION OF WOUND HEALING BY GROWTH HORMONE RELEASING HORMONE AND ITS AGONISTS

#91
20130261055
2013-10-03

N- and C- terminal substituted antagonistic analogs of GH-RH

#92
20130211045
2013-08-15

Macrocyclic modulators of the Ghrelin receptor

#93
20130195807
2013-08-01

Agonists of growth hormone releasing hormone as effectors for survival and proliferation of pancreatic islets

#94
20130189365
2013-07-25

Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces

#95
20130172242
2013-07-04

Growth hormone secretatogue receptor antagonists and uses thereof

#96
20130157951
2013-06-20

Pharmaceutical composition containing goserelin for in-situ implant

#97
20130157936
2013-06-20

Modulation of ghrelin levels and ghrelin/unacylated ghrelin ratio using unacylated ghrelin

#98
20130012439
2013-01-10

Composition for nasal administration and method for preparing same

#99
20130005654
2013-01-03

Therapeutic agent for accelerating recovery of animal under medical treatment

#100
20120264691
2012-10-18

Medical compositions containing ghrelin

#101
20120237476
2012-09-20

Pharmaceutical compositions for sustained release delivery of peptides

#102
20120232001
2012-09-13

Stable formulations for parenteral injection of peptide drugs

#103
20120135919
2012-05-31

Method for controllably releasing a drug conjugate within subcutaneous tissue in response to the local concentration of an indicator

#104
20120135918
2012-05-31

Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof

#105
20120129767
2012-05-24

Use of a ghrelin agonist to improve the catabolic effects of glucocorticoid treatment

#106
20120108511
2012-05-03

Preparation of biodegradable polyesters with low-burst properties by supercritical fluid extraction

#107
20120004174
2012-01-05

GH SECRETAGOGUES AND USES THEREOF

#108
20110245160
2011-10-06

Unacylated ghrelin fragments as therapeutic agent in the treatment of obesity

#109
20110230415
2011-09-22

Method for controlling fibrosis and other pathological deposits in tissues comprising administering a GHRP-6 composition

#110
20110166069
2011-07-07

Compositions and methods for stimulating gastrointestinal motility

#111
20110165195
2011-07-07

COMPOSITION FOR MUCOSAL ADMINISTRATION CONTAINING AGENT FOR ENHANCING MUCOSAL ABSORPTION OF PEPTIDE DRUG, AND ADMINISTRATION METHOD THEREOF

#112
20110160133
2011-06-30

Method for inhibiting inflammation and pre-inflammatory cytokine/chemokine expression using a ghrelin analogue

#113
20110160121
2011-06-30

UNACYLATED GHRELIN AND ANALOGS AS THERAPEUTIC AGENTS FOR VASCULAR REMODELING IN DIABETIC PATIENTS AND TREATMENT OF CARDIOVASCULAR DISEASE

#114
20110135661
2011-06-09

TREATMENT AND PREVENTION OF DRY AGE-RELATED MACULAR DEGENERATION BY ACTIVATING CD36

#115
20110112020
2011-05-12

MEASUREMENT OF G-PROTEIN mRNA IN THE DIAGNOSIS OF GROWTH HORMONE INSUFFICIENCY

#116
20110105390
2011-05-05

SELECTION AND TREATMENT OF PATIENTS SUFFERING FROM WASTING

#117
20110077195
2011-03-31

Liquid preparation of physiologically active peptide

#118
20110070640
2011-03-24

Optimized high yield synthetic plasmids

#119
20110034544
2011-02-10

Compositions comprising GHRH and GnRH and methods of using the same

#120
20110027251
2011-02-03

NOVEL USES FOR 4-PHENYLBUTYRATE (4PBA) AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS

#121
20110021429
2011-01-27

Renoprotection by growth hormone-releasing hormone and agonists

#122
20110003004
2011-01-06

Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces

#123
20100317581
2010-12-16

Ipamorelin Diacetate Injection and Infusion Solutions

#124
20100278924
2010-11-04

Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents

#125
20100267636
2010-10-21

USE OF CYTOCHROME P450-METABOLIZED DRUGS AND GRF MOLECULES IN COMBINATION THERAPY

#126
20100267635
2010-10-21

USE OF PROTEASE INHIBITORS AND GRF MOLECULES IN COMBINATION THERAPY

#127
20100247661
2010-09-30

Method of drug formulation of compositions comprising crystalline microparticle surfaces

#128
20100234677
2010-09-16

Reproductive management

#129
20100227806
2010-09-09

Use Of A Ghrelin Agonist To Improve Catabolic Effects Of Glucocorticoid Treatment

#130
20100216706
2010-08-26

Ghrelin Protects Substantia Nigra Dopamine Neurons

#131
20100209384
2010-08-19

Sustained release formulations comprising very low molecular weight polymers

#132
20100204118
2010-08-12

USE OF GRF-1 (1-29 ) AND CORTICOTROPIN-RELEASING FACTOR AS THERAPEUTIC AGENTS

#133
20100196396
2010-08-05

Compositions and methods for modulating ghrelin-mediated conditions

#134
20100168033
2010-07-01

UNACYLATED GHRELIN AS THERAPEUTIC AGENT IN THE TREATMENT OF METABOLIC DISORDERS

#135
20100152114
2010-06-17

Antioxidant activity of GH-RH Antagonists

#136
20100135979
2010-06-03

STABILIZED SUSPENSION

#137
20100130726
2010-05-27

Methods for reducing the mitogenicity of lectin compositions

#138
20100120682
2010-05-13

COMPOSITIONS FOR INCREASING BODY WEIGHT, USE AND METHODS

#139
20100104602
2010-04-29

Neurotoxin therapy for postprandial hyperglycemia

#140
20100093638
2010-04-15

TREAMENT FOR CHEMICAL SUBSTANCE ADDICTION

#141
20100093616
2010-04-15

Combination of EGF/GHRP-6 for Neurogeneration of Central Nervous System Following Autoimmune Damage

#142
20100087366
2010-04-08

GH secretagogues and uses thereof

#143
20100016226
2010-01-21

Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease

#144
20100010467
2010-01-14

Growth hormone releasing hormone treatment to decrease cholesterol levels

#145
20100009921
2010-01-14

Pharmaceutical compositions and methods for peptide treatment

#146
20090305969
2009-12-10

Skin Repair Accelerating Therapeutic Agent Containing Desacyl Ghrelin and Derivatives Thereof as Active Ingredient

#147
20090305957
2009-12-10

Preparation of biodegradable polyesters with low-burst properties by supercritical fluid extraction

#148
20090304724
2009-12-10

Compositions and methods for stimulating gastrointestinal motility

#149
20090292107
2009-11-26

COMPOSITION AND METHOD TO ALTER LEAN BODY MASS AND BONE PROPERTIES IN A SUBJECT

#150
20090253623
2009-10-08

GH secretagogues and uses thereof

#151
20090221512
2009-09-03

PHARMACEUTICAL COMPOSITION CONTAINING GHRP-6 TO PREVENT AND ELIMINATE FIBROSIS AND OTHER PATHOLOGICAL DEPOSITS IN TISSUES

#152
20090181888
2009-07-16

Skin Repair Accelerating Therapeutic Agent Containing Ghrelin and Derivatives Thereof or Substance Acting On GHS-R1a as Active Ingredient

#153
20090170748
2009-07-02

Gene therapy expression of GHRH for increasing RBC count in subjects

#154
20090163416
2009-06-25

Use of a ghrelin agonist to improve the catabolic effects of glucocorticoid treatment

#155
20090156474
2009-06-18

Methods for treating obesity and obesity related diseases and disorders

#156
20090143300
2009-06-04

Treatment of sepsis and septic shock using ghrelin and growth hormone

#157
20090088383
2009-04-02

GH SECRETAGOGUES AND USES THEREOF

#158
20090088380
2009-04-02

GHRH ANALOGS AND THERAPEUTIC USES THEREOF

#159
20090043074
2009-02-12

Use of ghrelin splice variant for treating cachexia and/or anorexia and/or anorexia-cachexia and/or malnutrition and/or lipodystrophy and/or muscle wasting and/or appetite-stimulation

#160
20090011985
2009-01-08

GH secretagogues and uses thereof

#161
20090005333
2009-01-01

REDUCING CULLING IN HERD ANIMALS GROWTH HORMONE RELEASING HORMONE (GHRH)

#162
20080312133
2008-12-18

Unacylated ghrelin as therapeutic agent in the treatment of metabolic disorders

#163
20080261873
2008-10-23

Growth-Hormone Secretagogues

#164
20080261872
2008-10-23

Use of ghrelin and unacylated ghrelin compositions for treating insulin resistance

#165
20080249017
2008-10-09

PHARMACEUTICAL FORMULATIONS OF GHRH MOLECULES

#166
20080221019
2008-09-11

Treatment of Inclusion Body Myositis

#167
20080193997
2008-08-14

Liquid Preparation of Physiologically Active Peptide

#168
20080171700
2008-07-17

Use Of Secretagogue For The Teatment Of Ghrelin Deficiency

#169
20080167222
2008-07-10

Use of growth hormone releasing factor analogs in treating patients suffering from wasting

#170
20080081787
2008-04-03

Medical compositions containing ghrelin

#171
20080020016
2008-01-24

Pharmaceutical compositions for sustained release delivery of peptides

#172
20080004217
2008-01-03

TREATMENT OF HIV-ASSOCIATED DYSMORPHIA/DYSMETABOLIC SYNDROME (HADDS) WITH OR WITHOUT LIPODYSTROPHY

#173
20070265191
2007-11-15

Pharmaceutical compositions and methods for peptide treatment

#174
20070219114
2007-09-20

Preventives or remedies for hepatopathy

#175
20070203069
2007-08-30

GRF-containing lyophilized pharmaceutical compositions

#176
20070123461
2007-05-31

Reproductive management

#177
20070110811
2007-05-17

Methods for reducing the mitogenicity of lectin compositions

#178
20070099820
2007-05-03

Polymer-drug conjugates

#179
20070066540
2007-03-22

Growth hormone secretagogue receptor type 1A agonists

#180
20070066532
2007-03-22

Compositions and methods for treatment of muscle pain and muscle wasting

#181
20070059374
2007-03-15

Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces

#182
20070059373
2007-03-15

Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents

#183
20070042409
2007-02-22

Mammalian obestatin receptors

#184
20070025991
2007-02-01

Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation

#185
20060293233
2006-12-28

Compositions and methods for modulating body weight and treating obesity-related disorders

#186
20060276381
2006-12-07

Remedy for diabetes

#187
20060252682
2006-11-09

Liquid growth hormone formulation and process of preparation thereof

#188
20060241054
2006-10-26

Growth hormone-releasing peptides in the treatment or prevention of atherosclerosis and hypercholesterolemia

#189
20060234905
2006-10-19

Method of stimulating growth and resistance to diseases of aquatic organisms

#190
20060217296
2006-09-28

Use of ghrelin for treating malnutrition in gastrectomized individuals

#191
20060188988
2006-08-24

Optimized high yield synthetic plasmids

#192
20060188555
2006-08-24

Therapeutic peptide formulations with improved stability

#193
20060183685
2006-08-17

PEPTIDE PHARMACEUTICAL FORMULATIONS

#194
20060166871
2006-07-27

Medical compositions containing ghrelin

#195
20060160739
2006-07-20

GRF-containing lyophilized pharmaceutical compositions

#196
20060134130
2006-06-22

Oral drug delivery compositions and methods

#197
20060069031
2006-03-30

Use of GnRH agonists to support the luteal phase during infertility treatment

#198
20060063807
2006-03-23

Low molecular weight peptidomimetic growth hormone secretagogues

#199
20060039862
2006-02-23

Identification and use of growth hormone secretagogue receptor type 1A antagonists

#200
20050267280
2005-12-01

Lactone bearing absorbable polymers

#201
20050255138
2005-11-17

Active agent transport systems

#202
20050232867
2005-10-20

Pharmaceutical compositions and methods for peptide treatment

#203
20050201938
2005-09-15

Method for selectively inhibiting ghrelin action

#204
20050197288
2005-09-08

GH secretagogues and uses thereof

#205
20050182014
2005-08-18

Reducing arthritis and lameness in subjects by growth hormone releasing hormone (GHRH) supplementation

#206
20050164952
2005-07-28

Delivery system for growth hormone releasing peptides

#207
20050130900
2005-06-16

Sustained release drug formulations containing a carrier peptide

#208
20050106209
2005-05-19

Composition and apparatus for transdermal delivery

#209
20050075290
2005-04-07

Compositions and methods for treating ileus

#210
20050014675
2005-01-20

Cell migration inhibitor

#211
20050009746
2005-01-13

Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy